Follistatin-315: A Circulating Activin-Binding Protein Studied in Muscle and Fibrosis Research

Research summary. Follistatin is a secreted glycoprotein originally isolated from ovarian follicular fluid as a follicle-stimulating hormone (FSH) inhibitor. It exists in two principal isoforms generated by alternative splicing — Follistatin-315 (FST-315) and Follistatin-288 (FST-288) — together with a 300-residue proteolytic intermediate. FST-315 is the predominant circulating form in plasma and acts primarily by binding and neutralising activin A and other ligands of the TGF-β superfamily, including myostatin (GDF-8) and GDF-11.

Molecular profile

• Length: 315 amino acids (mature, secreted form)
• Molecular weight: ~35 kDa (mature glycoprotein)
• Class: Secreted glycoprotein with three follistatin domains plus an N-terminal domain
• Synonyms: FST-315, activin-binding protein, FSH-suppressing protein
• Predominant location: Circulating in plasma (relative to FST-288, which preferentially binds heparan sulfate on cell surfaces)

The two isoforms differ in their C-terminal regions: FST-315 retains an acidic tail that prevents heparin binding, allowing it to circulate freely, whereas FST-288 lacks this tail and binds avidly to cell-surface proteoglycans, restricting it to a tissue-bound pool. The two isoforms are thus pharmacologically complementary rather than redundant.

Mechanism of action

Follistatin functions as a high-affinity, irreversible decoy receptor for activin A and related TGF-β superfamily ligands. By forming a tight 2:1 complex (two follistatin molecules per activin dimer), follistatin sequesters the ligand and prevents engagement of the activin receptor (ActRIIA/B). The downstream consequences are tissue-specific:

• In skeletal muscle: Sequestration of myostatin and activin A removes a brake on muscle hypertrophy, with downstream effects on Smad2/3 signalling and protein synthesis pathways.
• In endocrine pituitary: Modulation of activin signalling alters FSH secretion (the original context of follistatin's discovery).
• In tissue inflammation and fibrosis: Reduced TGF-β superfamily signalling dampens fibroblast activation, ECM deposition, and inflammatory remodelling.

Preclinical research highlights

Skeletal muscle hypertrophy. Foundational work by Lee and colleagues established that genetic ablation of myostatin produces dramatic muscle hypertrophy ("mighty mice") and that follistatin overexpression in muscle yields a similar — and additive — phenotype, consistent with antagonism of myostatin and at least one additional muscle-restraining ligand (likely activin A) [1]. This body of work has supported continued interest in follistatin and follistatin-derived strategies in research relevant to sarcopenia, cachexia, and muscular dystrophy.

Inflammation and fibrosis. Animal models of rheumatoid arthritis, asthma, and pulmonary fibrosis have reported attenuation of pathological remodelling with follistatin administration, attributed to neutralisation of activin A overexpression. Reductions in TGF-β-driven smooth muscle actin expression have been described in radiation-induced fibrosis models.

Vascular and renal protection. Endothelial-cell preparations have shown improved survival and revascularisation following ischaemic challenge with follistatin treatment, and rodent kidney-injury models have reported reduced cell death, oxidative damage, and fibrotic remodelling.

Biomarker role. Circulating follistatin levels have been reported to rise in cardiovascular disease and in selected oncological contexts, supporting interest in plasma follistatin as a research biomarker.

Comparison with FST-288

FST-288 (the heparin-binding isoform) and FST-315 (the circulating isoform) bind activin and myostatin with comparable affinity in vitro but are distributed differently in vivo. FST-288 dominates at the cell surface, where it is more readily internalised and degraded, while FST-315 dominates in plasma and is the more durable systemic neutraliser. Studies comparing the two isoforms in transgenic and gene-therapy contexts have generally favoured the circulating form for systemic muscle-mass effects in mice.

Regulatory and ethical considerations

Follistatin and follistatin-related peptides are listed by the World Anti-Doping Agency as prohibited substances under category S4 (hormone and metabolic modulators), and gene-therapy applications using follistatin transgenes have been the subject of explicit anti-doping policy attention. Any research on systemic follistatin biology in human-subject contexts is subject to substantial regulatory oversight.

Current research status

Follistatin-315 remains an investigational research protein. Recombinant follistatin and follistatin-derived therapeutics have entered early clinical development for indications including muscular dystrophy and inclusion body myositis (notably ACE-083 and ACE-031 from Acceleron Pharma, which targeted related activin pathways), with mixed clinical results to date. No follistatin-based product has received broad marketing authorisation.

For the research community, FST-315 remains:

• A research tool for studying activin-myostatin biology
• A reference protein in muscle-mass and fibrosis research
• A candidate for biomarker and gene-therapy investigation

Key takeaways for researchers

• Follistatin-315 is the predominant circulating isoform of follistatin, a high-affinity decoy receptor for activin A, myostatin, and related TGF-β superfamily ligands.
• It differs from FST-288 in that it does not bind heparan sulfate, allowing free circulation.
• Reported activity spans muscle hypertrophy, anti-fibrotic effects, vascular and renal protection, and biomarker roles.
• Follistatin is on the WADA Prohibited List and is not an approved therapeutic in mainstream regulatory jurisdictions.

References

1. Lee SJ. Regulation of muscle mass by myostatin. Annual Review of Cell and Developmental Biology. 2004;20:61–86.
2. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proceedings of the National Academy of Sciences USA. 1987;84(23):8282–8286.

---

This article is provided for educational and research purposes only. Follistatin-315 is a research protein. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. Follistatin and follistatin-derived therapeutics are listed by the World Anti-Doping Agency as prohibited substances. All work involving this protein should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.